1. Home
  2. |Insights
  3. |Properly Construed Claim May Not Cover All Embodiments

Properly Construed Claim May Not Cover All Embodiments

Client Alert | 1 min read | 04.23.07

In Intamin Ltd. V. Magnetar Technologies, Corp. (No. 05-1546, 1579, April 18, 2007), a Federal Circuit panel vacates part of a district court’s claim construction involving a magnetic braking system for amusement park rides and remands on the issue of non-infringement. On appeal, the parties dispute the district court’s construction of two limitations of the independent claim.

The first limitation involves “an intermediary disposed between adjacent pairs of said plurality of magnets” forming a portion of the brake assembly. The district court construed the term “intermediary” without determining the meaning of “adjacent magnets with alternating polarities”, leaving a question of whether the intermediary can be another magnet, and whether the accused brakes infringe. The panel looks at the understandable meaning of the term and the context of the patent, and finds that “intermediary” can include magnetic substances, but only if “alternating polarity” requires magnets of opposite polarity, a matter to be determined on remand.

The second limitation regards “said at least one conductive rail being adapted to extend the length of the fixed device part”, questioning if “length” refers to the full length of the fixed part, as construed by the district court, or to the orientation of the conductive rail. The specification uses “length” consistently with its meaning as a distance rather than a direction, says the panel. The proper claim construction may result in the claim not covering an embodiment described in the specification, but the patentee may draft different claims to cover different embodiments. The district court was thus correct in recognizing that “length” is not used to refer to direction or orientation.

Insights

Client Alert | 5 min read | 04.23.26

CMS Proposes New Payment Policy for IOPOs and HCLs

In keeping with ongoing efforts to intensify regulatory oversight of organ procurement organizations (OPOs) and curtail improper spending within federal health programs, the Centers for Medicare & Medicaid Services (CMS) recently issued a proposed rule that would, among other adjustments, align Medicare payment policies for non-renal organs to be consistent with those currently applicable to kidneys. If enacted as drafted, this latest rule could have a direct impact on the financial stability of OPOs and histocompatibility laboratories (HCL) at a time when such organizations face increasing pressure to meet CMS’s new outcome measures — or else face non-renewal or decertification later this year. ...